Swedish Agency Approves NsGene for Alzheimer's Drug Trial
Posted on: Thursday, 13 December 2007, 15:00 CST
Danish biotechnology company NsGene has said that its clinical trial application to start a Phase Ib study of NsG0202 for Alzheimer's disease has been approved by the Swedish Medical Products Agency.
NsG0202 consists of an implantable encapsulated cell (EC) biodelivery device that secretes nerve growth factor (NGF). NGF has shown to have neuroprotective and regenerative effects when delivered to relevant areas of the brain. NsG0202 is aimed at treating the progressive dementia associated with AD. It is expected that the initial three patients will have the EC biodelivery device implanted in the beginning of 2008. In all, six patients will participate in this Phase Ib study, which will run for one year.
Teit Johansen, president & CEO of NsGene, said: "This landmark achievement brings NsGene a step closer to a breakthrough for a treatment of this devastating disease and, by entering the clinic, the company has risen to the next level of corporate development including partnering opportunities for a maximal exploitation of our NsG0202 product."
Source: Datamonitor
Related Articles
- BioPartnering Europe 2008 Conference
- Alzheimer's Disease and Emerging Treatments Analyzed in Neurotech Insights
- Now In Its Fourth Year, 'The CNS Market 2008 Report' Is an Expanded and Updated 400 Page Report of Brain and Nervous System Markets and Treatments
- Researchers Report Neublastin Virtually Restores Complete Long-Term Sensory Motor Function in Preclinical Studies
- Focus on the Alzheimer's and Parkinson's Disease Drugs Market: Drug Classification, Future Therapies and Key Players
- Alzheimer's Therapeutics Reviewed By NeuroInvestment
- Get a Deep Insight into The CNS (Central Nervous System) Therapeutics Market
- Neurotechnology Industry Report Says Revenues Grew 10% to $120.5 Billion
- Anti-Alzheimer's Disease Drugs (Cholinesterase Inhibitors, and NMDARA), and Anti-Parkinson's Disease Drugs (Dopaminergic Agents, and Dopamine Agonists) Are Classified Inside 2006 Global Strategic Business Report
 |
 |
User Comments (0)
RSS Feeds